Korea's 3.5 Trillion Won Bet on the Next Obesity Drug Race

The deal that changes the math

Korean biotech companies have spent years building assets that Western pharma giants happily licensed for modest upfront payments and long-tail royalties. Hanmi Pharma’s announcement on August 24 with Genentech shatters that script.

The company agreed to sell exclusive development and commercialization rights for its obesity candidate HM17321 to the Roche subsidiary for up to $2.3 billion — roughly 3.5 trillion won. An upfront payment of $190 million hits Hanmi’s bank account immediately. That single number alone is noteworthy; it exceeds what most Korean biotechs have ever collected on a pre-revenue asset.

The full deal size places it among the top five license-out transactions in Korean biotech history. Only two deals eclipse it: a $4.7 billion oral Alzheimer’s asset between AriBio and Fosun Pharma, and Avila Bio’s platform agreement — neither of which involves a single candidate drug aimed squarely at the world’s hottest therapeutic category.

This is different. This is a Korean-developed, first-in-class obesity molecule moving directly into the hands of the company that defines how big pharma approaches these assets.

Why this matters beyond the price tag

The obesity drug market is worth more than $100 billion annually by some estimates, and the next generation of candidates is where the real competition lies. Eli Lilly and Novo Nordisk dominate with GLP-1-based therapies like Mounjaro and Wegovy. Those drugs work — they reduce weight substantially. But they have a blind spot that researchers and clinicians have flagged repeatedly: patients lose fat, but they also lose lean mass. Muscle. Bone. The kind of tissue that matters for metabolic health and quality of life in older patients.

HM17321 is not a GLP-1. It is a sustained-release analog of urocortin-2, a naturally occurring peptide that activates the corticotropin-releasing factor receptor system. Hanmi calls it a non-incretin mechanism. The distinction is the whole point. Preclinical data showed the molecule reduces body fat while preserving lean muscle mass — something no approved GLP-1 therapy achieves on its own.

Even more interesting, the data showed the drug works alongside GLP-1 therapies. That opens a pathway to fixed-dose combination products, which is exactly the direction Genentech is already moving. Roche is simultaneously advancing its own GLP-1 candidate ensifentrine (CT-388) and an amylin analog petrelintide through clinical development, and has signaled intent to combine them into a single formulation. Adding HM17321 gives Genentech a third mechanism — non-incretin — that complements the incretin and amylin axes already in its pipeline.

In other words, this deal is not just about one drug. It is about portfolio architecture in a market where the winning companies will be those that can offer patients multiple pathways to the same outcome.

Who wins, who loses, who waits

Hanmi Pharma wins a massive cash infusion at a stage when most Korean biotechs are still burning through their reserves on clinical trials. The $190 million upfront payment funds Phase 1 completion and likely extends the company’s runway by several years. The milestone payments that follow — tied to Phase 2 initiation, regulatory approval, and commercial launch — could add billions more if the drug succeeds, which the preclinical data suggest is plausible.

Genentech wins access to a differentiated mechanism at a time when every major pharmaceutical company is desperate to diversify beyond GLP-1. The obesity market will not stop growing, but the competitive landscape is about to become crowded with next-generation candidates. Having a non-incretin option in the pipeline is strategic insurance.

Eli Lilly and Novo Nordisk lose nothing directly, because Genentech does not have regulatory rights in Korea — Hanmi retains those. But they lose the advantage of a narrow therapeutic landscape. If HM17321 reaches market and demonstrates meaningful lean mass preservation, it could set a new clinical expectation for obesity treatment. Physicians who previously accepted muscle loss as the cost of weight reduction may begin to demand better. That puts pressure on the incumbent GLP-1 portfolio to justify their position beyond sheer weight-loss magnitude.

Other Korean biotechs may feel a shadow fall over their own licensing negotiations. This deal establishes a new reference point for what a differentiated obesity asset from Korea is worth. Companies with similar early-stage programs will face tougher questions from buyers who now have a ceiling to compare against.

The timing is not accidental

Hanmi received IND approval from the FDA in November 2025. Phase 1 is currently underway in healthy volunteers and obese patients, evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics. The company plans to complete Phase 1 and then hand the development baton to Genentech for Phase 2 onward. This is standard licensing structure, but the speed of execution is notable — the transition from FDA IND approval to a $2.3 billion deal in less than a year suggests the data were strong enough to move quickly.

Roche’s leadership has been explicit about positioning metabolic disease as a growth pillar. Boris L. Zaitra, Roche’s head of corporate business development, framed the HM17321 acquisition as addressing an important unmet medical need — selective fat reduction with muscle preservation. That language is deliberate. It signals that Roche is not buying this drug to match GLP-1 competitors on weight-loss numbers alone. It is buying it to compete on a different dimension of outcomes.

What happens next

Phase 1 readouts from Hanmi will be the first public data point. If the safety and tolerability profile is clean — and early signals suggest it is — Genentech will move HM17321 into Phase 2, likely in combination with ensifentrine or other GLP-1 agents. Combination trials are where the real story will emerge, because that is where the lean mass preservation advantage becomes clinically visible.

Regulatory timelines are uncertain. Even with a favorable Phase 2, obesity drug approvals have become a contested space. The FDA is scrutinizing long-term safety signals across the class. Genentech will need to build a differentiating safety narrative, not just an efficacy one.

For Korean biotech, the signal is clear: the era of licensing out for modest upfront payments and hoping for milestones is ending. The companies that will command blockbuster deals are those with differentiated mechanisms in the right therapeutic areas, backed by data that cannot be ignored. HM17321 is not guaranteed success. But the deal structure itself — $190 million on day one, $2.3 billion total, Genentech as buyer — tells you where the market is heading.

The obesity drug race is no longer just about who can lower weight the most. It is about who can deliver that result without breaking the patient’s metabolism, their muscles, or their long-term health. Hanmi Pharma just proved that Korea can build molecules that compete on that new standard.